

## Special Issue

# Intraoperative Radiation Therapy in the Treatment of Cancer

### Message from the Guest Editor

Intraoperative Radiation Therapy (IORT) has a long history in cancer treatment and became part of the armamentarium of radiation oncologists more than a century ago. The biologic effect of the large dose delivered during surgery is considered to be 2–3 times higher than the same doses delivered with a standard dose/fraction treatment, thus allowing dose escalation with the aim of improving local control, particularly if associated with external beam radiotherapy. Over recent decades, the development of mobile radiation generating machines, located in shielded operating rooms, made this procedure much easier to perform, obviating the need for patient transferral to the radiotherapy department. Breast cancer, intra-abdominal cancers, soft tissue sarcomas and many other cancer sites can be treated with IORT. This Special Issue will focus on the most important experiences with this radiotherapy technique at different cancer sites and debate the possible future developments of this radiotherapy modality.

### Guest Editor

Dr. Renzo Mazzarotto

Department of Radiotherapy, Verona University Hospital, Piazzale A. Stefani, 1-37126 Verona, Italy

### Deadline for manuscript submissions

closed (31 May 2022)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/83797](https://mdpi.com/si/83797)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)